 xxxd2072xxx : the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.   xxxd2072xxx  ( xxxd2072xxx ,  xxxd2072xxx ((r)) novartis) is the first oral inhibitor of mtor (mammalian  xxxg1478xxx ) to reach the oncology clinic.  xxxd2072xxx  10 mg daily achieves complete inhibition of its target at below the maximum tolerable dose for most patients. a phase iii randomized placebo-controlled trial has examined the impact of  xxxd2072xxx  in patients with clear cell renal cancers and progressive disease on or within 6 months of the vegfr  xxxg2198xxx  inhibitors sunitinib and/or sorafenib. the primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, p < 0.001) and 25% were still progression-free after 10 months of  xxxd2072xxx  therapy. there was a delay in time to decline of performance status and trends to improvement in quality of life, disease-related symptoms, and overall survival despite crossover of the majority of patients assigned to placebo. in 2009,  xxxd2072xxx  was approved in the us and europe as the only validated option for this indication. toxicities are usually mild to moderate and can be managed with dose reduction or interruption if necessary. opportunistic infections and non-infectious pneumonitis are seen as a class effect. management of common practical management issues are discussed. clinical trials are in progress to examine additional roles for  xxxd2072xxx  in renal cancer, alone and in combination with other agents.advanced renal cancer; drug therapy;  xxxd2072xxx 